Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Director · Chief Executive Officer · 10% owner | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axsome Therapeutics, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,229 |
Ending reported balance
After 2026-08-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-05 · Exercise / conversion · Acquired 45,004 · Balance 52,233 F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Row 2 · 2026-08-05 · Sale · Disposed 45,004 · Balance 7,229 F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $209.28 and $216.35. Row 3 · 2026-08-06 · Exercise / conversion · Acquired 4,660 · Balance 11,889 F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Row 4 · 2026-08-06 · Sale · Disposed 4,660 · Balance 7,229 F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $212.41 and $216.36. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $212.01 · Expires 2027-03-15 | Direct | 4,660 |
Reported balance
After 2026-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-05 · Exercise / conversion · Disposed 45,004 · Balance 4,660 F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $213.95 · Expires 2027-03-15 | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-06 · Exercise / conversion · Disposed 4,660 · Balance 0 F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,344,500 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 7,344,500 F6: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.
F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $209.28 and $216.35.
F5: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $212.41 and $216.36.
F6: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 7, 2026 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,660 | $0.00 Strike: $213.95 | $0.00 |
DisclosureSEC source: 0001193125-26-340688 · ownership.xml · derivative · entry 7 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 4,660 | $213.95 | $997,007.00 |
DisclosureSEC source: 0001193125-26-340688 · ownership.xml · nonDerivative · entry 4 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $212.41 and $216.36. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 4,660 | $4.95 | $23,067.00 |
DisclosureSEC source: 0001193125-26-340688 · ownership.xml · nonDerivative · entry 3 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,004 | $0.00 Strike: $212.01 | $0.00 |
DisclosureSEC source: 0001193125-26-340688 · ownership.xml · derivative · entry 6 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 45,004 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 45,004 | $212.01 | $9,541,298.04 |
DisclosureSEC source: 0001193125-26-340688 · ownership.xml · nonDerivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $209.28 and $216.35. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 45,004 | $4.95 | $222,769.80 |
DisclosureSEC source: 0001193125-26-340688 · ownership.xml · nonDerivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,666 | $0.00 Strike: $240.25 | $0.00 |
DisclosureSEC source: 0001193125-26-292985 · ownership.xml · derivative · entry 4 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,664 Underlying: Common Stock · 49,666 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 49,666 | $240.25 | $11,932,256.50 |
DisclosureSEC source: 0001193125-26-292985 · ownership.xml · nonDerivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $237.64 and $244.71. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 49,666 | $4.95 | $245,846.70 |
DisclosureSEC source: 0001193125-26-292985 · ownership.xml · nonDerivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| June 09, 2026 Filed Jun 9, 2026 21:17 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,670 | $0.00 Strike: $241.01 | $0.00 |
DisclosureSEC source: 0001193125-26-264038 · ownership.xml · derivative · entry 4 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,330 Underlying: Common Stock · 49,670 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| June 09, 2026 Filed Jun 9, 2026 21:17 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 49,670 | $241.01 | $11,970,966.70 |
DisclosureSEC source: 0001193125-26-264038 · ownership.xml · nonDerivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $236.11 and $244.13. Read SEC document |
| June 09, 2026 Filed Jun 9, 2026 21:17 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 49,670 | $4.95 | $245,866.50 |
DisclosureSEC source: 0001193125-26-264038 · ownership.xml · nonDerivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| April 21, 2026 Filed Apr 24, 2026 01:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantPerformance Stock Units · Derivative | 24,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-174417 · ownership.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,081 Underlying: Common Stock · 24,081 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date. F2 · derivative.expiration_date: Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date. Read SEC document |
| February 26, 2026 Filed Feb 28, 2026 00:10 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 54,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-083609 · ownership.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,623 Underlying: Common Stock · 54,623 shares Expires 2036-02-26 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 23:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 32,410 | $0.00 Strike: $185.60 | $0.00 |
DisclosureSEC source: 0001193125-26-033973 · ownership.xml · derivative · entry 4 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,410 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 23:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 32,410 | $185.60 | $6,015,296.00 |
DisclosureSEC source: 0001193125-26-033973 · ownership.xml · nonDerivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $183.85 and $186.89. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 23:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 32,410 | $8.02 | $259,928.20 |
DisclosureSEC source: 0001193125-26-033973 · ownership.xml · nonDerivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,261 | $0.00 Strike: $170.38 | $0.00 |
DisclosureSEC source: 0001193125-26-006695 · ownership.xml · derivative · entry 10 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,410 Underlying: Common Stock · 31,261 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 31,261 | $170.38 | $5,326,249.18 |
DisclosureSEC source: 0001193125-26-006695 · ownership.xml · nonDerivative · entry 6 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F6 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $168.15 and $173.17. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 31,261 | $8.02 | $250,713.22 |
DisclosureSEC source: 0001193125-26-006695 · ownership.xml · nonDerivative · entry 5 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,450 | $0.00 Strike: $172.33 | $0.00 |
DisclosureSEC source: 0001193125-26-006695 · ownership.xml · derivative · entry 9 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,671 Underlying: Common Stock · 29,450 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 29,450 | $172.33 | $5,075,118.50 |
DisclosureSEC source: 0001193125-26-006695 · ownership.xml · nonDerivative · entry 4 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $170.36 and $175.26. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 29,450 | $8.02 | $236,189.00 |
DisclosureSEC source: 0001193125-26-006695 · ownership.xml · nonDerivative · entry 3 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 78,703 | $0.00 Strike: $171.28 | $0.00 |
DisclosureSEC source: 0001193125-26-006695 · ownership.xml · derivative · entry 8 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,121 Underlying: Common Stock · 78,703 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 78,703 | $171.28 | $13,480,249.84 |
DisclosureSEC source: 0001193125-26-006695 · ownership.xml · nonDerivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $168.58 and $178.60. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 78,703 | $8.02 | $631,198.06 |
DisclosureSEC source: 0001193125-26-006695 · ownership.xml · nonDerivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 00:39 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,558 | $0.00 Strike: $148.18 | $0.00 |
DisclosureSEC source: 0001193125-25-308354 · ownership.xml · derivative · entry 10 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,824 Underlying: Common Stock · 10,558 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 00:39 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 10,558 | $148.18 | $1,564,484.44 |
DisclosureSEC source: 0001193125-25-308354 · ownership.xml · nonDerivative · entry 6 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F6 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $146.77 and $149.41. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 00:39 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 10,558 | $8.02 | $84,675.16 |
DisclosureSEC source: 0001193125-25-308354 · ownership.xml · nonDerivative · entry 5 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 00:39 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,163 | $0.00 Strike: $146.94 | $0.00 |
DisclosureSEC source: 0001193125-25-308354 · ownership.xml · derivative · entry 9 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,382 Underlying: Common Stock · 20,163 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 00:39 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 20,163 | $146.94 | $2,962,751.22 |
DisclosureSEC source: 0001193125-25-308354 · ownership.xml · nonDerivative · entry 4 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $142.66 and $148.39. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 00:39 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 20,163 | $8.02 | $161,707.26 |
DisclosureSEC source: 0001193125-25-308354 · ownership.xml · nonDerivative · entry 3 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:39 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,252 | $0.00 Strike: $144.59 | $0.00 |
DisclosureSEC source: 0001193125-25-308354 · ownership.xml · derivative · entry 8 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,545 Underlying: Common Stock · 49,252 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:39 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 49,252 | $144.59 | $7,121,346.68 |
DisclosureSEC source: 0001193125-25-308354 · ownership.xml · nonDerivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $141.79 and $149.23. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:39 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 49,252 | $8.02 | $395,001.04 |
DisclosureSEC source: 0001193125-25-308354 · ownership.xml · nonDerivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 00:01 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,775 | $0.00 Strike: $134.49 | $0.00 |
DisclosureSEC source: 0001193125-25-267467 · ownership.xml · derivative · entry 10 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 251,797 Underlying: Common Stock · 21,775 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 00:01 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 21,775 | $134.49 | $2,928,519.75 |
DisclosureSEC source: 0001193125-25-267467 · ownership.xml · nonDerivative · entry 6 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F6 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $131.60 and $135.49. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 00:01 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 21,775 | $8.02 | $174,635.50 |
DisclosureSEC source: 0001193125-25-267467 · ownership.xml · nonDerivative · entry 5 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 00:01 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,459 | $0.00 Strike: $133.79 | $0.00 |
DisclosureSEC source: 0001193125-25-267467 · ownership.xml · derivative · entry 9 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 273,572 Underlying: Common Stock · 50,459 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 00:01 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 50,459 | $133.79 | $6,750,909.61 |
DisclosureSEC source: 0001193125-25-267467 · ownership.xml · nonDerivative · entry 4 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $131.50 and $135.90. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 00:01 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 50,459 | $8.02 | $404,681.18 |
DisclosureSEC source: 0001193125-25-267467 · ownership.xml · nonDerivative · entry 3 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 00:01 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 91,705 | $0.00 Strike: $132.34 | $0.00 |
DisclosureSEC source: 0001193125-25-267467 · ownership.xml · derivative · entry 8 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 324,031 Underlying: Common Stock · 91,705 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 00:01 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 91,705 | $132.34 | $12,136,239.70 |
DisclosureSEC source: 0001193125-25-267467 · ownership.xml · nonDerivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $124.16 and $137.59. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 00:01 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 91,705 | $8.02 | $735,474.10 |
DisclosureSEC source: 0001193125-25-267467 · ownership.xml · nonDerivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 01:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,774 | $0.00 Strike: $118.84 | $0.00 |
DisclosureSEC source: 0001193125-25-234881 · ownership.xml · derivative · entry 10 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 415,736 Underlying: Common Stock · 12,774 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 01:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 12,774 | $118.84 | $1,518,062.16 |
DisclosureSEC source: 0001193125-25-234881 · ownership.xml · nonDerivative · entry 6 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F6 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $117.73 and $119.96. Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 01:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 12,774 | $8.02 | $102,447.48 |
DisclosureSEC source: 0001193125-25-234881 · ownership.xml · nonDerivative · entry 5 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 01:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,390 | $0.00 Strike: $118.77 | $0.00 |
DisclosureSEC source: 0001193125-25-234881 · ownership.xml · derivative · entry 9 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 428,510 Underlying: Common Stock · 13,390 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 01:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 13,390 | $118.77 | $1,590,330.30 |
DisclosureSEC source: 0001193125-25-234881 · ownership.xml · nonDerivative · entry 4 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $117.53 and $119.66. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 01:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 13,390 | $8.02 | $107,387.80 |
DisclosureSEC source: 0001193125-25-234881 · ownership.xml · nonDerivative · entry 3 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.